dermatology

News

Lilly scores with two Olumiant trials in atopic dermatitis

Eli Lilly has two positive trials of its JAK inhibitor Olumiant in skin disorder atopic dermatitis (AD), which could finally unlock the drug’s potential in the US.

R&D

Biotech strategy and nanomedicine: the pharmaphorum podcast

For episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The Wellcome Coll

News

J&J's Tremfya outperforms Novartis' Cosentyx in psoriasis

A large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had previously set standards in moderate to severe disease.

News

NICE okays UCB's Cimzia, nixes Almirall's Ilumetri, in psori...

NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for m

News

Sanofi to continue with cost-cutting as new drugs show promi...

Sanofi is to push on with cost-cutting after reaching a target of 1.5 billion euros a year ahead of expectations, amid mounting sales for new drugs.

News

NICE okays funding for Novartis skin cancer combo

The combination of the Novartis drugs dabrafenib and trametinib for patients with stage 3 skin cancer will be funded by the NHS in England and Wales after a recommendation from cost regulat

Lilly scores with two Olumiant trials in atopic dermatitis

Biotech strategy and nanomedicine: the pharmaphorum podcast

J&J's Tremfya outperforms Novartis' Cosentyx in psoriasis

NICE okays UCB's Cimzia, nixes Almirall's Ilumetri, in psori...

Sanofi to continue with cost-cutting as new drugs show promi...

NICE okays funding for Novartis skin cancer combo

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

dermatology

Editor's Picks